68Ga-grazytracer PET/CT 改进非小细胞肺癌化疗免疫治疗早期疗效评估:支气管动脉与静脉化疗比较
该前瞻性研究纳入60例晚期非小细胞肺癌患者,分别接受支气管动脉灌注(BAI)或静脉化疗免疫治疗,于1-2周期后行68Ga-grazytracer PET/CT。BAI组SUVmax更高(2.86±0.71 vs 2.19±0.80,P=0.001),客观缓解率更高(60.71% vs 34.38%,P=0.04);SUVmax对客观缓解有强判别价值(总体校正AUC=0.89),且为唯一独立早期疗效指标。
要点
- 68Ga-grazytracer PET/CT的SUVmax可早期预测晚期NSCLC化疗免疫治疗客观缓解,校正AUC=0.89。
- BAI组SUVmax和客观缓解率均高于静脉组,提示可能增强免疫激活。
- SUVmax判别准确性在BAI组(校正AUC=0.97)高于静脉组(校正AUC=0.83)。
核心结论
- 68Ga-grazytracer PET/CT是晚期NSCLC化疗免疫治疗早期疗效的有前景影像生物标志物,尤其在BAI方案患者中。
研究设计与样本
- 前瞻性研究纳入60例晚期NSCLC患者,接受BAI(n=28)或静脉(n=32)化疗免疫治疗,于1-2周期后行68Ga-grazytracer PET/CT。
- 主要终点为6个月客观缓解(iRECIST),次要终点比较组间免疫激活及该PET/CT与常规生物标志物的早期疗效评估性能。
- 统计分析包括ROC曲线分析、logistic回归和bootstrap内部验证。
主要发现
- BAI组SUVmax高于静脉组(2.86±0.71 vs 2.19±0.80,P=0.001),客观缓解率也更高(60.71% vs 34.38%,P=0.04)。
- SUVmax对客观缓解总体表观AUC=0.90,乐观校正后AUC=0.89,为唯一独立早期疗效指标。
- SUVmax判别准确性在BAI组表观AUC=0.99、校正AUC=0.97,静脉组表观AUC=0.83、校正AUC=0.83。
- SUVmax优于解剖学指标(SLD:AUC=0.57;ΔSLD:AUC=0.63)和PD-L1表达(AUC=0.45)。
- 肿瘤-血比值 corroborative 性能与SUVmax无显著差异。
关键数值与推荐
- 主要终点:6个月客观缓解按iRECIST评估。
- BAI组客观缓解率60.71%,静脉组34.38%(P=0.04)。
- SUVmax总体表观AUC=0.90,乐观校正AUC=0.89。
- BAI组SUVmax表观AUC=0.99、校正AUC=0.97;静脉组表观AUC=0.83、校正AUC=0.83。
- SLD的AUC=0.57,ΔSLD的AUC=0.63,PD-L1表达的AUC=0.45。
临床怎么用
- 对接受化疗免疫治疗的晚期NSCLC患者,可在1-2周期后行68Ga-grazytracer PET/CT,以SUVmax早期预测客观缓解。
- BAI方案患者中SUVmax判别准确性更高,可优先考虑该影像评估。
- SUVmax优于常规解剖学指标和PD-L1表达,可作为补充评估工具。
局限性
- 需要更大规模、统一方案的验证研究来确认这些发现并评估临床实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemoimmunotherapy outperforms immunotherapy alone in advanced non-small cell lung cancer (NSCLC). However, current anatomical imaging and programmed death-ligand 1 (PD-L1) assessments are insufficient for early response prediction and do not directly capture treatment-induced immune effector function. Whether 68Ga-grazytracer PET/CT, which visualizes granzyme B as a marker of CD8+ T‑cell effector function, could assess early response and reveal potential differences between intravenous and bronchial arterial infusion (BAI)-based chemoimmunotherapy remains unknown. METHODS: In this prospective study, 60 patients with advanced NSCLC receiving BAI-based (n = 28) or intravenous (n = 32) chemoimmunotherapy underwent 68Ga-grazytracer PET/CT after 1-2 treatment cycles. The primary endpoint was a 6-month objective response (iRECIST). Secondary endpoints compared immune activation between groups and the performance of 68Ga-grazytracer PET/CT for early response assessment versus conventional biomarkers (baseline tumor size [SLD], early anatomical change [ΔSLD], and PD-L1 expression). Statistical analyses included ROC curve analysis, logistic regression, and bootstrap internal validation. RESULTS: BAI-based chemoimmunotherapy showed higher 68Ga-grazytracer uptake (maximum standardized uptake value [SUVmax]: 2.86 ± 0.71 vs. 2.19 ± 0.80, P = 0.001) and objective response rate (60.71% vs. 34.38%, P = 0.04) than intravenous chemoimmunotherapy, suggesting a possible association with enhanced immune activation. The SUVmax demonstrated strong discriminative value for objective response (overall apparent AUC = 0.90; optimism-corrected = 0.89) and was the only independent early-response indicator, outperforming anatomical response metrics (SLD: AUC = 0.57; ΔSLD: AUC = 0.63) and PD-L1 expression (AUC = 0.45). The discriminative accuracy of the SUVmax was higher in the BAI cohort (apparent AUC = 0.99; corrected = 0.97) than in the intravenous cohort (apparent AUC = 0.83; corrected = 0.83). The corroborative performance of the tumor-to-blood ratio was not significantly different from that of SUVmax. CONCLUSIONS: 68Ga-grazytracer PET/CT is a promising early imaging biomarker for the response to chemoimmunotherapy in advanced NSCLC patients, particularly those receiving BAI-based regimens. Larger validation studies with uniform protocols are needed to validate these findings and assess its clinical utility. TRIAL REGISTRATION: ChiCTR2500105792, the registration date is 2025-07-10, https://www.chictr.org.cn/showproj.html?proj=275165 .
引用
- Shen X, Wang Z, Xia Z, et al. Improved early response assessment of chemoimmunotherapy efficacy by 68Ga-grazytracer PET/CT in non-small cell lung cancer: a comparison of bronchial arterial versus intravenous chemotherapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 42303867. doi:10.1007/s00259-026-08012-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。